Key facts
- The GLP-1 market in China, India, and Brazil is projected to reach $22 billion by 2035.
- The current market size for these drugs in the three countries is $6.6 billion.
- J.P. Morgan forecasts an annual growth rate of 15% for this market through 2035.
- China's GLP-1 market is expected to reach $13.7 billion by 2035, surpassing Brazil's $8 billion market.
The market for GLP-1 drugs used for weight loss and diabetes treatment in China, India, and Brazil is projected to expand significantly by 2035, according to a J.P. Morgan note. Analysts estimate the combined market could reach $22 billion, up from $6.6 billion currently, with an annual growth rate of 15%. This growth is attributed to increasing affordability, broader access, and the large patient populations suffering from diabetes and obesity in these countries. China and India together account for over 40% of the world's diagnosed diabetes cases. J.P. Morgan anticipates China will surpass Brazil as the largest market among the three by 2027, driven by its substantial diabetes burden and wider reimbursement policies for GLP-1 therapies. While Brazil is currently the largest market, its penetration rate is expected to remain lower than in the US. India faces challenges such as conservative attitudes towards injectables and affordability concerns, which remain barriers to adoption.